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Purpose: The purpose of this study was to evaluate the efficacy and safety of Montelukast sodium in 
the prevention of bronchopulmonarydysplasia (BPD).
Methods: The Interventional study was designed as a multicenter, prospective, and randomized trial, 
with open labeled and parallel-experimental groups, 66 infants were enrolled and allocated to either 
the case group (n=30)  or the control group (n=36) based on gestational age (GA). Infants in the case 
group were given Montelukast sodium (Singulair) based on their body weight (BW). Zero week was 
defined as the start time of the study.
Results: The incidence of moderate to severe BPD was not different between the groups (case group: 
13 of 30 [43.3%] vs. control group: 19 of 36 [52.8%], P=0.912). Additionally, secondary outcomes 
such as ventilation index, mean airway pressure and resort to systemic steroids were not significantly 
different. There were no serious adverse drug reactions in either group, and furthermore the rate of 
occurrence of mild drug related-events were not significantly different (case group: 10 of 42 [23.8%] 
vs. control group: 6 of 48 (15.8%), P=0.414).
Conclusion: Montelukast was not effective in reducing moderate or severe BPD. There were no 
significant adverse drug events associated with Montelukast treatment.
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Introduction 
Recent advances in medical treatments of bronchopulmonary dysplasia (BPD), such as 
the use of antenatal steroids, surfactant therapy, and mechanical ventilation have increased 
survival rates in preterm infants; however BPD remains, a major complication of preterm 
infants1,2). The incidence of BPD at 36 weeks postmenstrual age (PMA) is reported as 16%–
39% in preterm infants born at less than 32 weeks gestation, or in infants with very low 
birth weight3-5). Infants born at less than 28 weeks gestation had an incidence of 40%–52% 
BPD at 36 weeks PMA6,7). Thus, BPD clearly remains a significant problem in preterm 
infants. 
In 1975, Philip8) proposed that the etiology of BPD was multifactorial, mostly composed 
of external factors, such as exposure to oxygen and pressure. Inflammatory responses were 
subsequently introduced in the etiological paradigm, including external sources (chorio-
amnionitis, postnatal infections), iatrogenic sources (ventilation, oxygen), and the internal 
host response9). Even though this paradigm is confirmed by experimental data, few 
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innovative therapies have proven efficacious10). Vitamin A, caffe-
ine, postnatal corticosteroids, and stem cells from cord blood may 
help in repairing the preterm lung. Specific anti-inflammatory 
treatments hold some promise, but developing drugs for use in 
infants is a challenging task11,12).
Leukotrienes, metabolites of arachidonic acid, have potent 
chemotactic activity towards polymorph nuclear leukocytes. They 
play an important role in chronic pulmonary inflammation13), 
and are associated with hyperoxia and inhibition of alveolariza-
tion14). In accordance with this role, several studies on leuko-
trienes in BPD have been conducted recently. Sheikh et al.15) and 
Joung et al.16) reported that infants with clinical BPD have higher 
levels of urinary leukotriene E4.
Montelukast sodium is a selective cysteinyl leukotriene receptor 
antagonist with proven clinical benefit in the treatment of asthma 
and perennial allergic rhinitis, in adults and children as young as 
6 months of age. Its efficacy and safety in children younger than 
6 months is not yet established. Knorr et al.17) and Kearns et al.18), 
reported in their pharmacokinetics and safety study of Monte-
lukast in children 1 to 3 and 3 to 6 months of age, that admini-
stration of a single dose of Montelukast (4 mg) was generally well 
tolerated.
The effect of Montelukast on BPD in neonatal intensive care 
setting have been published19), but it had small population and 
retrospective design. Therefore we performed this study in order 
to determine the efficacy and safety of Montelukast on BPD in 
preterm infants, with prospective, randomized trial.
Materials and methods
1. Study design and population
This study was a multicenter, prospective, randomized, open 
labeled, parallel group, intervention trial. All protocols were 
approved by the Institutional Review Board at each site, and the 
studies were conducted in compliance with the Korea Food and 
Drug Administration. This study was registered in clinical trials 
database (clinicaltrials.gov, ID: NCT01717625). A parent or 
guardian provided written informed consent for every infant 
included in the study. We selected the participant number based 
on earlier clinical trials by Ambalavanan et al.20) with vitamin A 
(where superiority limit was set to 10%); as well as a study on 
BPD by Dani et al.21) with incidence confirmed at 40%. They re-
ported the combination of death and BPD (BPD/death) between 
inhaled nitric oxide and control groups, and the proportion of the 
BPD/death of control group was 90%. Based on these data, we 
assumed that the difference of morbidity and mortality of BPD 
between two groups is 40%, and the rate of morbidity and mor-
tality of BPD is 90%. Accordingly, statistical power 80%, type I 
error 0.025 was set. In addition, we included 72 patients based on 
a previous study with 60 patients with a 20% exclusion rate.
2. Inclusion and exclusion criteria
Inclusion criteria were preterm infants born at less than 32 
weeks gestational age (GA); infants 14 days after birth on oxygen 
or mechanical ventilation; infants with more than 20 calories per 
kilogram per day by enteral feeding; All inclusion and partici-
pation in clinical trials was by signed parental consent. Exclusion 
criteria were any of the following: infants with congenital ano-
maly; infants from who blood sampling for pharmacokinetics 
was impossible due to cardiovascular collapse; in addition, any 
cases in which clinical trials were deemed difficult by the investi-
gator. Examinees confirmed by inclusion criteria, were registered 
in the trial and allocated to case or control groups (1:1) by ran-
dom assignment, stratified by GA (>28 weeks, ≤28 weeks), using 
shuffled blocks of random numbers in Microsoft Office, Excel 
2007. Infants assigned to the test group, were given Montelukast 
sodium according to body weight (less than 1,000 g, 0.5 mg; 
1,000 g to 1,500 g, 1.0 mg; 1,500 g to 2,000 g, 1.5 mg; greater 
than 2,000 g, 2 mg). The drug was given once daily via oroga-
stric tube or by oral administration, at a given time. Each infant 
was treated until 36 weeks GA or until discharge. The body 
weight was measured every week to determine accuracy of 
dosage. All enrolled patients received surfactant treatment.
All clinical assessments and data collections were performed 
prospectively by local investigators, who were all trained pedi-
atricians. The evaluation of data included: (1) efficacy of the drug, 
(2) safety of the drug, and (3) pharmacokinetic evaluation. Zero 
week was defined as the start time of the study.
3. Efficacy
The efficacy of the drug was evaluated by incidence and se-
verity of BPD (primary outcome)22). In secondary outcome, we 
evaluated ventilation index [VI=R×(PIP–PEEP)×PaCO2/1,000], 
mean airway pressure {MAP=[R×It×PIP+(60–R×It×PEEP)]/60} 
(R, rate; PIP, peak inspiratory pressure; PEEP, positive end 
expiratory pressure; It, inspiratory time). We also evaluated usage 
of mechanical ventilation, oxygen, systemic steroid and change 
in body weight. Systemic steroid was used only for rescue therapy 
of BPD. The principles of ventilator therapy was reflected by 
recent ventilator trend (early extubation and nasal continuous 
positive airway pressure after surfactant treatment), through the 
meeting. 
4. Safety
The safety of the drug was evaluated by the rate of adverse 
events and classified by System Organ Classes (SOC) classifica-
tion. Each adverse event was also classified by intensity, progress, 
complication, and treatment-causal relationship. 
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5. Pharmacokinetic study
Seven of 36 Montelukast groups who agreed to inclusion in 
pharmacokinetic studies, were divided into A and B groups by 
using shuffled blocks of random numbers. In each center, subjects 
were also further divided according to sampling time, as single 
dose study groups as follows; A group: at 2, 6 hours after medi-
cation, B group: at 4, 24 hours after medication; and as multi ple 
dose study group as follows: A group: at 2,6 hours on the 7th day 
post medication, B group: at 4,24 hours on the 7th day post 
medication. Pharmacokinetic samples were analyzed using 
BioInfra (Seoul, Korea). Quantification of Montelukast was done 
by ultra performance liquid chromatography–mass spec trometry 
(MS)/MS. The results were calculated as follows: C=1/x2 by linear 
regression using MassLynx V4.1 (Waters Co., Milford, MA, USA) 
{C=concentration, x=[Montelukast peak area/Internal standards 
(ISTD) peak area]×ISTD concentration}. Each preterm infant was 
evaluated for ventilating mode (mode, fiO2, MAP, oxygen index), 
medication history, weight, associated disease (intraventricular 
hemorrhage [IVH], hemodynamically significant patent ductus 
arteriosus, necrotizing entrocolitis [NEC], pneu monia, sepsis), 
laboratory data (hemoglobin [Hb], hematocrit, platelet count, 
blood urea nitrogen, creatinine, aspartate transa minase, alanine 
transaminase, and blood culture). Proinflamatory cytokines were 
measured in intubated infants only at the time of enrollment, and 
weekly upto 2 weeks after taking medicine. We set the end point 
of the studies as 36 weeks GA, or the discharge date.
6. Statistical analysis
The results were presented as mean and standard deviation for 
continuous variables, and frequency and percentage for catego-
rical variables. The superiority test with R 2.14.1 (R Foundation 
for Statistical Computing, Vienna, Austria) was used for primary 
outcome. The secondary efficacy rating variables between two 
groups are done by t test and Fisher exact test. The t test was used 
for ventilation index and mean airway pressure. Fisher exact test 
was used for demographic data, usage of mechanical ventila tion 
and steroids.
The safety of the drug evaluation was performed by Fisher 
exact test comparing the incidence and severity of adverse reac-
tion, as well as causality of adverse with drug administration, 
between two groups. Vital signs, physical examinations, and 
laboratory results are evaluated by descriptive statistic compari-
sons between two groups. 
7. Pharmacokinetic modeling
Pharmacokinetic modeling was done with a single compart-
mental model. Because of insufficient information about the 
absorption period, the modeling of intravenous administration 
which excludes absorption modeling, was assumed. Based on 
this, covariate analyses like age, weight, and sex were added. The 
evaluation of the developed model was done by three methods: 
(1) relative standard error (standard error/estimate value) where 
sensitivity of parameter estimate value less than 50% is reliable, 
(2) visual inspection 1: comparison of similarity between 
longitudinal progress of the predicted value and observed value, 
(3) visual inspection 2: in the group of individual, evaluate bias 
whether weighted residual is distributed around a line of zero 
(weighted residual=residual/observed value).
Results
1. Study population 
A total of 83 infants enrolled in 5 units, but only 77 infants 
constituted the study group; 1 infant was excluded due to lack of 
parental consent, 1 infant based on exclusion criteria, 1 infant due 
to excess number, and 3 infants for violation of medication 
protocol. Among the 77 infants, 37 enrolled in the case group and 
40 in the control group. 7 infants of the case group were 
terminated early; 3 infants were excluded for onset of comor-
bidity; 1 infant for treatment with phenobarbital; 1 infant for the 
lack of parental consent; 1 infant for protocol violation; 1 infant 
based on the researcher’s opinion. Four infants of the control 
group were terminated early; 2 infants for medication of Mon-
telukast; and 2 infants for protocol violation (Fig. 1). The charac-
teristics of the patients in the 2 groups are shown (Table 1). There 
was no difference in birth weight (case group: 1,097±327.3 g vs. 
control group: 997±235.3 g, P=0.153) and GA (case group: 27.6 
±1.4 weeks vs. control group: 27.3±1.6 weeks, P=0.374) between 
the two groups, at birth. Additionally, there were no significant 
differences in other characteristics (Apgar scores, usage of ante-
natal steroid, the incidence once, and IVH). 
Fig. 1. Participant flow. We selected the participant number based on 
earlier clinical trials by Ambalavanan et al.20) with vitamin A (where 
superiority limit was set to 10%); as well as a study on bronch opul-
monarydysplasia (BPD) by Dani et al.21) with incidence confirmed at 40%. 
They reported the combination of death and BPD (BPD/death) between 
NO and control groups, and the proportion of the BPD/death of control 
group was 90%. Based on these data, we assumed that the differ ence of 
morbidity and mortality of BPD between two groups is 40%, and the rate 
of morbidity and mortality of BPD is 90%. Accordingly, statistical power 
80%, type I error 0.025 was set. In addition, we included 72 patients 
based on a previous study with 60 patients with a 20% exclusion rate.
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(thrombocytopenia, anemia) (Table 4). Intensity of adverse events 
was more severe in case group (case group: 11 vs. control group: 
0, P=0.023). However, most of the adverse reactions were evaluat-
ed as unlikely to be causally related to Montelukast treatment 
(data not shown). The laboratory findings demon strated that the 
number of clinically significant (CS) abnormal platelet count was 
increased significantly in the case group (case group: 6 vs. control 
group: 1, P=0.043), while the number of nonclinically significant 
(NCS) abnormal platelet count was increased in the control group 
rather than case group. There were no significant differences 
between groups in the other laboratory findings (Table 5). Import-
antly, there were no significant differences in CS rate [CS/(normal 
+NCS)] of Hb (case group: 0.01 vs. control group: 0.00, P=0.621), 
platelet count (case group: 0.02 vs. control group: 0.00, P=0.066), 
blood culture (case group: 0.05 vs. control group: 0.03, P=0.489) 
and other laboratory findings (data not shown).
2. Efficacy 
The incidence of moderate to severe BPD was not different 
between the groups. (case group: 43.3% vs. control group: 52.8%, 
P=0.912) (primary outcome, Table 2). There were no significant 
differences in FiO2 at 2 weeks after treatment (case group: 0.28% 
±0.07% vs. control group: 0.29%±0.08%, P=0.472); MAP (case 
group: 6.33±2.25 mmHg vs. control group: 8.63±1.92 mmHg, P= 
0.062); ventilation index (case group: 23.1±13.8 vs. control group: 
18.5±9.6, P=0.507); need of invasive ventilator (case group: 7 of 
30 [23.30%] vs. control group: 7 of 36 [19.40%], P=0.131), use of 
systemic steroids for rescue therapy of BPD (case group: 7 of 30 
[23.3%] vs. control group: 7 of 36 [19.4%], P=0.768) (secondary 
outcome, Table 3).
3. Safety 
The rate of adverse event did not differ between the groups 
(case group: 10 of 42 [23.8%] vs. control group: 6 of 32 [15.8%], 
P=0.414). There were no serious adverse drug events. According 
to SOC classification, the most common adverse event is infection 
(case group: 8 vs. control group 3, total 11). These included 
staphylococcal bacteremia, other sepsis, candida infection, and 
septic shock. Next are gastrointestinal disorders (abdominal 
distension, NEC, ileus); abnormal serum chemistry (elevation of 
liver enzyme); and blood and lymphatic system disorders 
Table 1. Comparisons of demographic data of studygroups
Variable Case group (n=30)
Control group 
(n=36) P value
Gestational age (wk)
At birth   27.6±1.6   27.3±1.6 0.374
At 0 week   31.3±1.3   30.6±1.6 0.205
Weight (g)
At birth 1,097±327    997±235 0.153
At 0 week 1,328±305 1,199±328 0.107
Apgar score
1 Minute at screening   3 (2–5)   3 (2–5) 0.440
5 Minutes at screening   5 (4–7)   5 (4–7) 0.426
Antenatal steroid 11 (36.7) 17 (47.2) 0.458
NEC (stage≥II)   2 (6.7)   2 (5.6) 1.000
IVH (stage≥III)   0 (0)   3 (8.3) 0.245
Values are presented as mean±standard deviation, median (25%–75%) or 
number (%).
NEC, necrotizing enterocolitis; IVH, intraventricular hemorrhage. 
Table 2. Incidence and severity of bronchopulmonarydysplasia (BPD)
BPD Case group(n=30)
Control group
(n=36) P value
Mild 17 (56.7) 17 (47.2) 0.912
Moderate/severe 13 (43.3) 19 (52.8)
Values are presented as number (%).
Table 3. Comparison of secondary outcome parameters
Variable Case group(n=30)
Control group 
(n=36) P value
FiO2 at 2 weeks after treatment (%) 0.28±0.07   0.29±0.08 0.472
MAP at 2 weeks after Treatment (mmHg) 6.33±2.25   8.63±1.92 0.062
VI at 2 weeks after treatment 23.1±13.8 18.5±9.6 0.507
Need of ventilator at 2 weeks 0.131
Invasive   7 (23.3)   7 (19.4)
Noninvasive 17 (56.6) 25 (69.4)
None   6 (20.0)   4 (11.1)
Use of systemic steroid   7 (23.3)   7 (19.4) 0.768
Values are presented as mean±standard deviation or number (%).
MAP, mean airway pressure; VI, ventilation index; R, rate; PIP, peak inspiratory 
pressure; PEEP, positive end expiratory pressure; It, inspiratory time.
MAP=[R×It×PIP+(60–R×It×PEEP)]/60; VI=R×(PIP–PEEP)×PaCO2 /1,000.
Table 4. SOC classification of adverse events
SOC Case group Control group Total
Blood and lymphatic system disorders 2 1 3
Cardiac disorders 1 0 1
Gastrointestinal disorders 5 1 6
General disorders and administration site 
conditions
2 1 3
Hepatobiliary disorders 1 0 1
Infections and infestations 8 3 11
Investigations 4 6 10
Pregnancy, puerperium, and perinatal 
conditions
1 0 1
Renal and urinary disorders 2 0 2
Respiratory, thoracic, and mediastinal 
disorders
1 1 2
Vascular disorders 1 0 1
Total 28 13 41
SOC, System Organ Classes.
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4. Pharmacokinetic study
Seven infants from 3 units enrolled to the pharmacokinetic 
study. Among 17 infants, 9 enrolled in the single dose group and 
8 in the multiple dose group. Pharmacokinetic modeling using 
the modeling of intravenous administration (excluding absorp-
tion) and covariate analysis like age, weight, and sex resulted in 
the following:
TVV = θ1 • (CR/CRmed)
θ2
V = TVV • EXP (η)
TVCL = θ3 • (AGE/AGEmed)θ4
CL = TVCL
Y = PRED • (1+ε)
TVV is a typical value of volume of distribution, TVCL is a 
typical value of clearance, volume (V) and clearance (CL) are each 
individual value, CRmed and AGEmed are median value of the level 
of serum creatinine (CR) and the age of infant (AGE) (CRmed=0.6 
mg/dL, AGEmed=27.0 days). η is a random variable of inter-indi-
vidual difference, but clearance is not significant, a typical value 
of group reveals individual value. Y is an observed value, PRED is 
a predicted value, ε is a random variable related residual error or 
intraindividual difference. 
The concentration of Montelukast according to the time is 
shown (Fig. 2), the characteristics of the patients in the 2 groups 
were not significantly different. As shown in Table 6, each typical 
value of distribution volume and clearance is 918 mL and 5.12 
mL/hr. According to covariate analysis, the volume of distribution 
decreases as the serum creatinine concentration increases, and the 
clearance decreases as the age increases (P<0.0005). The relative 
standard error of estimated parameters is 7.2% to 34.6%, less than 
50%, thus the modeling results are reliable (Table 6). In the 1mg 
group with the highest number of participants, the predicted value 
(line) passes close to the center of observed values (dots), therefore, 
we concluded that the modeling was appropriate (Fig. 3).
Discussion
BPD originally described by Northway in 1967, comprised the 
clinical, radiologic and pathologic changes seen in infants with 
severe respiratory distress syndrome (RDS) or prolonged mecha-
nical ventilation and high inspiratory oxygen levels23). The lung 
pathology included inflammation, airway fibrosis and smooth 
muscle hypertrophy, alveolar collapse and hyperinflation and 
interstitial fibrosis of all tissues24). The “new BPD” cases are more 
compatible with an arrest in lung development than with mecha-
nical injury. Inflammation was introduced in this paradigm, thus 
including external sources (chorioamnionitis, postnatal infec-
tions), iatrogenic sources (ventilation, oxygen), and the internal 
host response9). Despite confirmation of this paradigm by experi-
mental data, few innovative therapies have proven efficacious10). 
Table 5. Summation of laboratory finding
Laboratory finding
Case group Control group
P value
NCS CS NCS CS
Blood culture 7 5 2 3 0.140
BUN (3–25 mg/dL) 157 2 173 0 0.212
Creatinine (0.3–1.2 mg/dL) 119 2 120 0 0.514
Hb (11.5–22.5 g/dL) 201 2 197 1 0.506
Hct (28%–69%) 176 2 173 1 0.620
Platelet (84,000–478,000×103/μL) 108 6 131 1 0.043
AST (10–140 U/L) 15 3 30 5 0.062
ALT (3–54 U/L) 28 5 23 5 0.642
WBC (5,000–34,000 ×103/μL) 75 3 81 1 0.617
Total 886 30 930 17 0.126
NCS, nonclinically significant; CS, clinically significant; BUN, blood urea 
nitrogen; Hb, hemoglobin; Hct, hematocrit; AST, aspartate transaminase; ALT, 
alanine transaminase; WBC, white blood cell.
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Fig. 2. Concentration of Montelukast over time. Seventeen infants in 3 
NICU, enrolled in the pharmacokinetic study. They were also divided at 
each center, according to sampling time. 9 enrolled in the single dose 
study groups (A group: at 2, 6 hours after medication; B group: at 4, 24 
hours after medication) and 8 enrolled in the multiple dose study group 
(A group: at 2,6 hours on the 7th day post medication; B group: at 4,24 
hours on the 7th day post medication). The concentration of Montelukast 
at different time points is shown.
Table 6. Pharmacokinetic parameters
Parameter Typical value CV (%) P-value
Volume (mL) 66.3 (34.6) <0.0005
Θ1 918 (18.7*)
Θ2 –1.63 (18.7*)
Clearance (mL/hr) <0.0005
Θ3 5.12 (16.3*) -
Θ4 –3.17 (7.2*) -
Weighted residual (%) 47.7 (23.5*)
CV (%): coefficient of variation.
*Relative standard error (%). 
http://dx.doi.org/10.3345/kjp.2015.58.9.347
Kim SB, et al. • Montelukast for bronchopulmonary dysplasia
352
Vitamin A, caffeine, postnatal corticosteroids, and stem cells from 
cord blood may help repair the preterm lung. Kim et al.19), re-
ported Montelukast as an adjunct therapy, in BPD. Montelukast (1 
mg/kg/day) was administered to 15 preterm infants with esta-
blished BPD for an average period of 12 weeks. Ventilation index 
was significantly improved after 2 weeks in the Mon telukast 
treatment group, and there were no differences in the incidence 
of adverse reaction between the 2 groups. While speci fic anti-
inflammatory treatments hold some promise, developing drugs 
for infants is a difficult task11,12).
In our study, there were no differences in predictors of efficacy, 
such as incidence and severity of BPD, FiO2, MAP, ventilation 
index, the need of ventilator, or the use of systemic steroid at 4 
weeks after taking medicine. And similar to previous studies that 
reported in pharmacokinetics and safety study of Montelukast in 
children 1 to 3 and 3 to 6 months of age17,18), administration of 
Montelukast was well tolerated. 
This multicenter, prospective, and randomised study, has limi-
tations. First, the protective effects of an effective drug must in-
volve the inhibition of leukotriene production and not be attri-
buted solely to anti-inflammatory mechanisms25). Leukotrienes 
are known mediators of hyperoxia-induced aberrant alveolari-
zation14,26,27). It has been suggested that apart from inflammatory 
processes, the mechanisms involved in Leukotrienes mediated 
aberration of alveolarizationmay require subtle alterations in the 
signal transduction pathways of growth factors and receptors 
involved in the alveolarization process. Based on these mecha-
nisms, instead of leukotriene receptor antagonist, other alternates 
under consideration are the leukotriene synthesis inhibitors, like 
5-lipoxygenase inhibitor (e.g., Zileuton) or 5-lipoxygenase-
activating protein inhibitor (e.g., MK-0591, not approved by Food 
and Drug Administration). Second, given the multifactorial 
etiology of BPD, these finding cannot be generalized. Chara-
feddine et al.28) subclassified BPD into two groups according to 
the criteria; ‘classic’ and ‘atypical’ BPD. ‘Atypical BPD’ was diag-
nosed in BPD cases without RDS or in BPD cases that were 
preceded by initial RDS that resolved within 10 days, and required 
no oxygen supplementation for at least 72 hours, beyond the 28-
day oxygen requirement. Joung et al.16) reported that although 
there was no significant difference between the no/mild and the 
moderate/severe BPD groups, when they compared ‘classic’ and 
‘atypical’ BPD groups, there was a significant increase in urinary 
LTE4 levels on day 7 in the ‘atypical’ BPD group. This observation 
has two interpretations. The evaluation of the incidence and 
severity of all BPD can mask that of ‘atypical BPD’, and secondly, 
the evaluation of the total treatment period can mask of the 
effects of the early period related to inflammatory insult. Third, 
the differences (40%) shown in previous studies21) might be 
exaggerated due to smaller sample size. If the sample size is 
increased by the participation of more units, the differences can 
decrease. Forth, the effectiveness of the orally given drug was 
influenced by variable volume of enteral feeds, they could influ-
ence drug availability and absorption from the gastrointes tinal 
tract. Fifth, considering the multicenter study, we do not stan-
dardize the protocol exactly for each center. (e.g., dosage of 
systemic steroid, protocol of ventilator therapy)
Several pediatric studies with Montelukast show that oral 
Montelukast is generally well tolerated29-31). Bisgaard et al.32) 
reported the safety and tolerability of Montelukast in a placebo-
controlled and open-labeled trial. The most common clinical 
adverse events they reported were upper respiratory infection, 
worsening pulmonologic problem, and fever. And there were no 
clinically meaningful differences in laboratory parameters. In 
addition, Sarkar et al.33) reported infant outcomes in a prospective 
study with Montelukast, during pregnancy. According to this 
research group, Montelukast does not appear to increase the basal 
rate of major malformations, moreover, the resultant lower birth 
weight was most likely associated with the severity of the 
maternal condition, rather than the treatment In our study, there 
was no serious adverse drug event, and known adverse event 
(described above) did not differ between the groups. 
In conclusion, Montelukast was not effective in reducing the 
moderate or severe BPD. Additionally, there was no significant 
increase in adverse drug event associated with Montelukast 
treatment. Nevetheless, this study is significant in that it is a first 
prospective study of Montelukast for preterm infant. Based on 
designing and finding from the present study, it is expected that 
further studies are needed on the relationship between BPD and 
leukotriene modifiers. 
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Fig. 3. Predicted (line) and observed values (dots) over time. The 1-mg 
group with the highest number of participants, predicted value (line) 
passes close to the center of observed values (dots), therefore, indicative 
of appropriate modeling. CONC, concentration; PRED, predicted value; 
Median, median value.
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